NEW YORK, Aug. 4, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split…


Previous articleCOMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Next articlePT344 – Susan Beaulieu – Epigenetics, Resilience, and Remembering